Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) EBITDA Margin (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed EBITDA Margin for 5 consecutive years, with 11756.21% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 1483656.0% year-over-year to 11756.21%, compared with a TTM value of 1105.95% through Dec 2025, down 1574419.0%, and an annual FY2025 reading of 1105.95%, up 3820693.0% over the prior year.
  • EBITDA Margin was 11756.21% for Q4 2025 at Aligos Therapeutics, down from 4251.28% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 13853.38% in Q1 2025 and bottomed at 100926.32% in Q3 2024.
  • Average EBITDA Margin over 5 years is 6795.69%, with a median of 1139.9% recorded in 2022.
  • The sharpest move saw EBITDA Margin plummeted -10008876bps in 2024, then surged 9667503bps in 2025.
  • Year by year, EBITDA Margin stood at 10085.01% in 2021, then surged by 98bps to 155.63% in 2022, then crashed by -368bps to 729.09% in 2023, then soared by 522bps to 3080.34% in 2024, then crashed by -482bps to 11756.21% in 2025.
  • Business Quant data shows EBITDA Margin for ALGS at 11756.21% in Q4 2025, 4251.28% in Q3 2025, and 1646.63% in Q2 2025.